ESMOLOL HYDROCHLORIDE

Post-LOE

esmolol hydrochloride in sodium chloride

Viatris (2)

ANDAINJECTIONINJECTABLE

Approved

Mar 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ESMOLOL HYDROCHLORIDE (esmolol hydrochloride in sodium chloride) by Viatris (2) is 1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Approved for noncompensatory sinus tachycardia where, the physician's judgment, the rapid heart rate requires specific intervention and 4 more indications. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

1 -selective (cardioselective) adrenergic receptor blocking agent with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Its elimination half-life after intravenous infusion is approximately 9 minutes.…

Indications (6)

noncompensatory sinus tachycardia where the physician's judgment

Worked on ESMOLOL HYDROCHLORIDE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.